Reports Q1 revenue $3.1M, consensus $2.19M. Cash, cash equivalents and investment totaled $27.2M as of March 31, 2024, which includes a $7.0M private placement financing which closed on March 19, 2024. “We continue to make steady progress in the training and activation of new treatment centers which is a testament to both the emerging role of HEPZATO in the treatment of patients with metastatic uveal melanoma and the capability and dedication of our field force,” said CEO Gerard Michel. “We are committed to expanding the availability of HEPZATO to patients in need and I am confident that we will reach our goal of 20 treating centers by the end of 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems’ Hepzato Kit in melanoma meets primary Phase 3 endpoint
- DCTH Upcoming Earnings Report: What to Expect?
- Delcath Systems files to sell 1.92M shares of common stock for holders
- Delcath Systems price target raised to $20 from $18 at H.C. Wainwright
- Delcath Systems, Inc. Under ESG Spotlight: Navigating New Compliance Challenges and Financial Implications